Literature DB >> 8299122

Cytotoxic susceptibility and defective MHC class I expression do not correlate with mutation of p53 in human carcinomas.

Z Végh1, P Wang, F Vánky, C Hising, K Sjöwall, B Larsson, E Klein.   

Abstract

Twenty-nine samples of ex vivo ovarian and lung carcinomas were investigated for the relationship between the presence of mutated protein 53 (mp53) and cytotoxic susceptibility. Unaltered expression of MHC class I alleles was required for the cytotoxic susceptibility of tumour cells to the autologous ex vivo blood lymphocytes, i.e. all 4 sensitive tumours belonged to the group of 11 tumours without defect in MHC class I expression. In contrast, the susceptibility did not correlate with the presence of mp53, i.e. cases with mp53 were randomly distributed between the sensitive and resistant tumours (2/4 and 10/17 respectively). There was no correlation either between the p53 mutation and down-regulation of MHC class I alleles. The results suggest that in these tumours the mutated p53 is not the source of immunogenic peptides and that the lack of recognition of the tumours with mp53 is not caused by a defect in the expression of MHC class I molecules.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8299122     DOI: 10.1007/BF01517173

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  12 in total

Review 1.  Toward a genetic analysis of tumor rejection antigens.

Authors:  T Boon
Journal:  Adv Cancer Res       Date:  1992       Impact factor: 6.242

2.  An improved biochemical method for the analysis of HLA-class I antigens. Definition of new HLA-class I subtypes.

Authors:  J J Neefjes; B S Breur-Vriesendorp; G A van Seventer; P Iványi; H L Ploegh
Journal:  Hum Immunol       Date:  1986-06       Impact factor: 2.850

3.  Auto-tumor recognition following in vitro induction of MHC antigen expression on solid human tumors: stimulation of lymphocytes and generation of cytotoxicity against the original MHC-antigen-negative tumor cells.

Authors:  F Vánky; G Stuber; S Rotstein; E Klein
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 4.  Role of the major histocompatibility complex class I antigens in tumor growth and metastasis.

Authors:  K Tanaka; T Yoshioka; C Bieberich; G Jay
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

5.  Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines.

Authors:  Y Yaginuma; H Westphal
Journal:  Cancer Res       Date:  1992-08-01       Impact factor: 12.701

6.  Selectively down-regulated expression of major histocompatibility complex class I alleles in human solid tumors.

Authors:  Z Végh; P Wang; F Vánky; E Klein
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

7.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.

Authors:  J Bártek; J Bártková; B Vojtĕsek; Z Stasková; J Lukás; A Rejthar; J Kovarík; C A Midgley; J V Gannon; D P Lane
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

8.  p53 mutations in human lung tumors.

Authors:  C W Miller; K Simon; A Aslo; K Kok; J Yokota; C H Buys; M Terada; H P Koeffler
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

9.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

Authors:  J V Gannon; R Greaves; R Iggo; D P Lane
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

10.  Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens.

Authors:  T Wölfel; E Klehmann; C Müller; K H Schütt; K H Meyer zum Büschenfelde; A Knuth
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.